Trial · NCT02285439
Adverse events1,116
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,116
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Level 1 | 0 | 4 | |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Level 2 | 0 | 3 | |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Level 3 | 1 | 3 | |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Level 4 | 0 | 3 | |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Level 5 | 1 | 6 | |
| other | Anemia | Blood and lymphatic system disorders | Phase II Stratum 1 | 0 | 27 | |
| other | Anemia | Blood and lymphatic system disorders | Phase II Stratum 2 | 2 | 21 | |
| other | Anemia | Blood and lymphatic system disorders | Phase II Stratum 3 | 0 | 30 | |
| other | Anemia | Blood and lymphatic system disorders | Phase II Stratum 4 (Surgical Arm, Target Validation) | 0 | 7 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Phase I Dose Level 1 | 0 | 4 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Phase I Dose Level 2 | 0 | 3 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Phase I Dose Level 3 | 0 | 3 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Phase I Dose Level 4 | 0 | 3 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Phase I Dose Level 5 | 0 | 6 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Phase II Stratum 1 | 0 | 27 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Phase II Stratum 2 | 1 | 21 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Phase II Stratum 3 | 1 | 30 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Phase II Stratum 4 (Surgical Arm, Target Validation) | 0 | 7 | |
| other | Sinus tachycardia | Cardiac disorders | Phase I Dose Level 1 | 0 | 4 | |
| other | Sinus tachycardia | Cardiac disorders | Phase I Dose Level 2 | 0 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02285439/events